Clinical trial
Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown…
NCT00193622 · SCRI Development Innovations, LLC, Other · Completed
Key facts
| NCT number | NCT00193622 |
|---|---|
| Title | Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site |
| Official title | A Phase II Trial of Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site |
| Lead sponsor | SCRI Development Innovations, LLC, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neoplasms, Unknown Primary |
| Intervention type | Drug |
| Interventions | Bevacizumab, Erlotinib |
| Enrollment | 50 |
| Start date | Apr 1, 2004 |
| Primary completion | Sep 1, 2005 |
| Completion | Jan 1, 2009 |
| First posted | Sep 19, 2005 |
| Last update posted | Sep 17, 2010 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: